InVivoMAb anti-mouse CD1d (CD1.1)

Pilones KA, Aryankalayil J, Babb JS, et al. Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. J Immunother Cancer. 2014,2(1):37. doi: 10.1186/s40425-014-0037-x

Hayworth JL, Mazzuca DM, Maleki Vareki S, et al. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens. Immunol Cell Biol. 2012,90(7):699-709. doi: 10.1038/icb.2011.90

Yang W, Li H, Mayhew E, et al. NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci. 2011,52(6):3094-102. doi: 10.1167/iovs.10-7067

Miellot-Gafsou A, Biton J, Bourgeois E, et al. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology. 2010,130(2):296-306. doi: 10.1111/j.1365-2567.2009.03235.x

Shi MQ, Wang CR, Wei GJ, et al. Experimental African trypanosomiasis: lack of effective CD1d-restricted antigen presentation. Parasite Immunol. 2006,28(12):643-7.

D'Souza CD, Cooper AM, Frank AA, et al. A novel nonclassic beta2-microglobulin-restricted mechanism influencing early lymphocyte accumulation and subsequent resistance to tuberculosis in the lung. Am J Respir Cell Mol Biol. 2000,23(2):188-93.

Szalay G, Ladel CH, Blum C, et al. Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta 2 and Th1 cytokines and ameliorates listeriosis in mice. J Immunol. 1999,162(12):6955-8.